Basis: Trailing twelve months (TTM net income over TTM revenue). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the net profit margin high or low?
The net profit margin of 2.94% is 102% above its 5-year average of -177.05%, near the high end of its 5-year range (-914.55%–359.16%).
101.07% above its 12-month average of -273.57%.
Reported quarterly profit margin; no daily interpolation. Q2 FY2026 (2026-06-30): 67.84%.
NET PROFIT MARGIN
2.94%
NET PROFIT MARGIN AVG TTM
-273.57%
NET PROFIT MARGIN AVG 3Y
-124.20%
NET PROFIT MARGIN AVG 5Y
-177.05%
NET PROFIT MARGIN AVG 10Y
-275.65%
NET PROFIT MARGIN AVG 15Y
N/A
NET PROFIT MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
+101.07%
CURRENT VS 3Y AVG
+102.37%
CURRENT VS 5Y AVG
+101.66%
CURRENT VS 10Y AVG
+101.07%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-0.02%
median of 811 covered companies
CURRENT VS SECTOR MEDIAN
+14800.00%
vs the sector median at left
Arvinas, Inc.
Market Cap
$473.59M
Net Profit Margin
2.94%
TTM Avg
-273.57%
3Y Avg
-124.20%
5Y Avg
-177.05%
Market Cap
$474.59M
Net Profit Margin
-3.06%
TTM Avg
-9.59%
3Y Avg
-17.39%
5Y Avg
-29.37%
Market Cap
$471.33M
Net Profit Margin
0.00%
TTM Avg
0.00%
3Y Avg
11.36%
5Y Avg
9.09%
Market Cap
$470.89M
Net Profit Margin
-38.37%
TTM Avg
-56.73%
3Y Avg
-82.08%
5Y Avg
-57.25%
Market Cap
$470.76M
Net Profit Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$468.69M
Net Profit Margin
-35.69%
TTM Avg
-57.08%
3Y Avg
-75.90%
5Y Avg
-92.95%
Market Cap
$486.09M
Net Profit Margin
11.55%
TTM Avg
13.38%
3Y Avg
8.98%
5Y Avg
-0.37%
Market Cap
$488.52M
Net Profit Margin
-10.85%
TTM Avg
-18.16%
3Y Avg
-29.23%
5Y Avg
-75.36%
| NAME | MARKET CAP | NET PROFIT MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Arvinas, Inc. (ARVN) | $473.59M | 2.94% | -273.57% | -124.20% | -177.05% |
| Cerus Corporation (CERS)vs › | $474.59M | -3.06% | -9.59% | -17.39% | -29.37% |
| Contineum Therapeutics, Inc. (CTNM)vs › | $471.33M | 0.00% | 0.00% | 11.36% | 9.09% |
| Alpha Teknova, Inc. (TKNO)vs › | $470.89M | -38.37% | -56.73% | -82.08% | -57.25% |
| Bright Minds Biosciences Inc. (DRUG)vs › | $470.76M | 0.00% | 0.00% | 0.00% | 0.00% |
| Kamada Ltd. (KMDA)vs › | $470.50M | 11.60% | 10.09% | 6.05% | 5.82% |
| Sight Sciences, Inc. (SGHT)vs › | $468.69M | -35.69% | -57.08% | -75.90% | -92.95% |
| Puma Biotechnology, Inc. (PBYI)vs › | $486.09M | 11.55% | 13.38% | 8.98% | -0.37% |
| Evolus, Inc. (EOLS)vs › | $488.52M | -10.85% | -18.16% | -29.23% | -75.36% |
| NRC Health (NRC)vs › | $458.62M | 4.18% | 12.88% | 16.89% | 20.14% |
Operating Margin
-43.8%
Net Profit Margin
2.9%
Net Profit Margin = Net Income / Revenue
Net profit margin is the percentage of revenue that becomes net income after all expenses, taxes, and interest.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | NET PROFIT MARGIN |
|---|---|
| 2026-06-30 | 67.84% |
| 2026-03-31 | -369.23% |
| 2025-12-31 | -709.47% |
| 2025-09-30 | -83.77% |
| 2025-06-30 | -273.21% |
| 2025-03-31 | 43.91% |
| 2024-12-31 | -76.18% |
| 2024-09-30 | -48.05% |
| 2024-06-30 | -46.01% |
| 2024-03-31 | -274.31% |
| 2023-12-31 | 359.16% |
| 2023-09-30 | -184.97% |
| 2023-06-30 | -122.20% |
| 2023-03-31 | -252.00% |
| 2022-12-31 | -218.16% |
| 2022-09-30 | -199.40% |
| 2022-06-30 | -207.10% |
| 2022-03-31 | -239.25% |
| 2021-12-31 | -201.52% |
| 2021-09-30 | -503.23% |
| 2021-06-30 | -914.55% |
| 2021-03-31 | -745.45% |
| 2020-12-31 | -1873.41% |
| 2020-09-30 | -405.70% |
| 2020-06-30 | -438.90% |
| 2020-03-31 | -348.40% |
| 2019-12-31 | -430.14% |
| 2019-09-30 | -58.82% |
| 2019-06-30 | -427.35% |
| 2019-03-31 | -358.63% |
| 2018-12-31 | -467.65% |
| 2018-09-30 | -396.64% |
| 2018-06-30 | -231.02% |
| 2018-03-31 | -101.02% |
| 2017-12-31 | -183.81% |
| 2017-09-30 | -383.33% |
| 2017-06-30 | -400.16% |
| 2017-03-31 | -374.25% |
